ANN ARBOR–Endra Life Sciences Inc. (NASDAQ: NDRA), developers of Thermo Acoustic Enhanced UltraSound (TAEUS) medical imaging technology, reported a loss of $2.4 million for the third quarter ended Sept. 30, compared to a loss of $3.1 million in the same quarter a year earlier. For the nine months, the loss for the development stage life science company was $7.5 million, compared to a loss of $8.6 million in the same nine months of 2023.
Endra’s TAEUS technology is being developed to assess tissue fat content and monitor tissue ablation during minimally invasive procedures, at the point of patient care. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD) and metabolic dysfunction-associated steatohepatitis (MASH), chronic liver conditions that affect over two billion people globally, and for which there are no practical diagnostic tools. For more information, visit www.endrainc.com.
“We are laser focused on securing the clinical data necessary to support a new De Novo regulatory filing with the FDA–above all other initiatives–and are encouraged by the subject recruitment progress at our pilot clinical evaluation sites,” said Alexander Tokman, Endra’s acting CEO. “In parallel, we are making significant progress with our go-to-market strategy for TAEUS to ensure we are prioritizing the most promising verticals, setting our longer-term vision and business strategy, while significantly reducing operating expenses to extend our cash runway.”